Tislelizumab, a PD-L1/PD-L2 signaling antagonist, has been noted for its ability to enhance cytokine production and reinvigorate T-cell function, which is crucial for the immune-mediated destruction of tumor cells (Zhang et al., 2018). This evidence concerns the gene CD274 and neoplasm.